FYERS
Home
/
Stocks
/
Profit Loss
/
CORONA Remedies Profit & Loss

CORONA Remedies Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
₹422 Cr₹353 Cr₹342 Cr₹361 Cr₹347 Cr₹294 Cr₹298 Cr₹314 Cr
₹3 Cr₹4 Cr₹2 Cr₹2 Cr₹2 Cr₹1 Cr₹76 L₹2 Cr
₹426 Cr₹357 Cr₹345 Cr₹363 Cr₹349 Cr₹295 Cr₹298 Cr₹316 Cr
₹343 Cr₹301 Cr₹269 Cr₹292 Cr₹286 Cr₹250 Cr₹238 Cr₹256 Cr
₹96 Cr₹66 Cr₹85 Cr₹81 Cr₹72 Cr₹56 Cr₹70 Cr₹69 Cr
₹3 Cr₹1 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr
₹80 Cr₹54 Cr₹55 Cr₹70 Cr₹61 Cr₹43 Cr₹58 Cr₹57 Cr
₹60 Cr₹45 Cr₹41 Cr₹52 Cr₹46 Cr₹31 Cr₹45 Cr₹43 Cr

Share Price Live Stats

Open (₹)2,121.00
Volume (₹)8,333.00
High (₹)2,150.40
Upper Circuit2,553.30
Low (₹)2,090.80
Lower Circuit1,702.30
Prev Close2,127.80
52W High (₹)2,270.10
Price2,094.30
52W Low (₹)1,336.60

Share Market Cap & Key Ratios Overview

M.Cap (₹)12992.50 Cr
Div. Yield (%)0.47
PE Ratio65.28
Debt to Equity0.19
Price to Book12.74
Book Value122.12
EPS (TTM)32.54
Face Value10.00
ROE (%)27.36

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
CORONANSE
LTP
1W Low
1W High
Market cap (₹)
1901.1-18.9 (-0.98%)
1896.80
1984.80
4,56,833Cr
9157-82 (-0.89%)
9087
9467
2,45,426Cr
4837-213 (-4.22%)
4823
5066
1,87,320Cr
1129.3-61.7 (-5.18%)
1125.10
1187
1,13,217Cr
1380.3-43.2 (-3.03%)
1376
1426.10
1,12,212Cr
1846.2-92.3 (-4.76%)
1811.70
1949
1,01,155Cr
2112.9-58.6 (-2.70%)
2107.20
2192
97,626Cr
2331.7-51.2 (-2.15%)
2327.30
2419.20
96,859Cr
1157.5-20.5 (-1.74%)
1154.40
1179.90
96,406Cr
1651.5+6.2 (0.38%)
1622.60
1717
93,614Cr
2094.3+14.8 (0.71%)
2020.20
2150.40
12,993Cr

Key Highlights of CORONA Remedies Ltd’s P&L

In 2026-03-31, CORONA Remedies Ltd reported total revenue of ₹1413.83Cr, compared with ₹1202.35Cr in 2025-03-31, reflecting CORONA Remedies Ltd turnover.

Depreciation was ₹37.87Cr and finance costs were ₹6.97Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹240.42Cr in 2026-03-31 as compared to ₹198.53Cr in 2025-03-31.

Net Profit (PAT) was ₹185.12Cr in 2026-03-31 compared with ₹149.43Cr in 2025-03-31.

Earnings per share (EPS) were ₹30.27 in 2026-03-31, compared with ₹24.43 in 2025-03-31.